vs
Protalix BioTherapeutics, Inc.（PLX）与SWK Holdings Corp（SWKH）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是SWK Holdings Corp的1.0倍（$9.1M vs $8.7M），SWK Holdings Corp同比增速更快（-29.7% vs -49.9%），SWK Holdings Corp自由现金流更多（$26.8M vs $1.6M），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -12.5%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
SWK Holdings Corp是一家专注于医疗健康与生命科学领域的专业金融企业，为生物技术、制药、医疗器械及诊断类企业提供特许权使用费货币化、结构性债务、资产支持贷款等定制化融资服务，核心市场以北美地区为主。
PLX vs SWKH — 直观对比
营收规模更大
PLX
是对方的1.0倍
$8.7M
营收增速更快
SWKH
高出20.2%
-49.9%
自由现金流更多
SWKH
多$25.1M
$1.6M
两年增速更快
PLX
近两年复合增速
-12.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $8.7M |
| 净利润 | $-5.5M | $-19.4M |
| 毛利率 | 49.4% | — |
| 营业利润率 | -51.1% | 9.9% |
| 净利率 | -60.3% | — |
| 营收同比 | -49.9% | -29.7% |
| 净利润同比 | -184.8% | -430.2% |
| 每股收益（稀释后） | $-0.06 | $-1.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXSWKH
| Q4 25 | $9.1M | $8.7M | ||
| Q3 25 | $17.9M | $10.9M | ||
| Q2 25 | $15.7M | $10.1M | ||
| Q1 25 | $10.1M | $11.8M | ||
| Q4 24 | $18.2M | $12.4M | ||
| Q3 24 | $18.0M | $10.4M | ||
| Q2 24 | $13.5M | $10.8M | ||
| Q1 24 | — | $11.4M |
净利润PLXSWKH
| Q4 25 | $-5.5M | $-19.4M | ||
| Q3 25 | $2.4M | $8.8M | ||
| Q2 25 | $164.0K | $3.5M | ||
| Q1 25 | $-3.6M | $4.5M | ||
| Q4 24 | $6.5M | $5.9M | ||
| Q3 24 | $3.2M | $3.5M | ||
| Q2 24 | $-2.2M | $3.7M | ||
| Q1 24 | — | $468.0K |
毛利率PLXSWKH
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
营业利润率PLXSWKH
| Q4 25 | -51.1% | 9.9% | ||
| Q3 25 | 11.9% | 61.3% | ||
| Q2 25 | 7.5% | 46.1% | ||
| Q1 25 | -41.0% | 68.6% | ||
| Q4 24 | 39.6% | 44.7% | ||
| Q3 24 | 22.2% | 39.2% | ||
| Q2 24 | -18.0% | 8.3% | ||
| Q1 24 | — | 9.5% |
净利率PLXSWKH
| Q4 25 | -60.3% | — | ||
| Q3 25 | 13.2% | 80.7% | ||
| Q2 25 | 1.0% | 35.2% | ||
| Q1 25 | -35.8% | 38.4% | ||
| Q4 24 | 35.6% | 47.5% | ||
| Q3 24 | 18.0% | 33.3% | ||
| Q2 24 | -16.4% | 33.9% | ||
| Q1 24 | — | 4.1% |
每股收益（稀释后）PLXSWKH
| Q4 25 | $-0.06 | $-1.59 | ||
| Q3 25 | $0.03 | $0.72 | ||
| Q2 25 | $0.00 | $0.29 | ||
| Q1 25 | $-0.05 | $0.37 | ||
| Q4 24 | $0.10 | $0.47 | ||
| Q3 24 | $0.03 | $0.28 | ||
| Q2 24 | $-0.03 | $0.30 | ||
| Q1 24 | — | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $42.8M |
| 总债务越低越好 | — | $33.0M |
| 股东权益账面价值 | $48.2M | $235.1M |
| 总资产 | $82.3M | $272.4M |
| 负债/权益比越低杠杆越低 | — | 0.14× |
8季度趋势，按日历期对齐
现金及短期投资PLXSWKH
| Q4 25 | $14.7M | $42.8M | ||
| Q3 25 | $13.6M | $10.2M | ||
| Q2 25 | $17.9M | $8.0M | ||
| Q1 25 | $19.5M | $29.8M | ||
| Q4 24 | $19.8M | $5.9M | ||
| Q3 24 | $27.4M | $17.2M | ||
| Q2 24 | $23.4M | $5.5M | ||
| Q1 24 | — | $5.5M |
总债务PLXSWKH
| Q4 25 | — | $33.0M | ||
| Q3 25 | — | $33.0M | ||
| Q2 25 | — | $33.0M | ||
| Q1 25 | — | $33.0M | ||
| Q4 24 | — | $33.0M | ||
| Q3 24 | — | $33.0M | ||
| Q2 24 | — | $33.0M | ||
| Q1 24 | — | $33.0M |
股东权益PLXSWKH
| Q4 25 | $48.2M | $235.1M | ||
| Q3 25 | $52.9M | $254.2M | ||
| Q2 25 | $49.9M | $246.5M | ||
| Q1 25 | $45.2M | $292.7M | ||
| Q4 24 | $43.2M | $288.7M | ||
| Q3 24 | $32.4M | $283.4M | ||
| Q2 24 | $28.6M | $282.8M | ||
| Q1 24 | — | $279.9M |
总资产PLXSWKH
| Q4 25 | $82.3M | $272.4M | ||
| Q3 25 | $82.3M | $289.4M | ||
| Q2 25 | $78.5M | $285.7M | ||
| Q1 25 | $73.9M | $331.3M | ||
| Q4 24 | $73.4M | $332.2M | ||
| Q3 24 | $61.6M | $321.3M | ||
| Q2 24 | $91.5M | $321.0M | ||
| Q1 24 | — | $322.0M |
负债/权益比PLXSWKH
| Q4 25 | — | 0.14× | ||
| Q3 25 | — | 0.13× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.12× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $27.3M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $26.8M |
| 自由现金流率自由现金流/营收 | 17.8% | 308.1% |
| 资本支出强度资本支出/营收 | 4.4% | 5.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-13.6M | $43.2M |
8季度趋势，按日历期对齐
经营现金流PLXSWKH
| Q4 25 | $2.0M | $27.3M | ||
| Q3 25 | $-3.7M | $906.0K | ||
| Q2 25 | $-5.2M | $7.8M | ||
| Q1 25 | $-5.1M | $8.3M | ||
| Q4 24 | $4.0M | $23.0M | ||
| Q3 24 | $4.1M | $6.3M | ||
| Q2 24 | $-3.6M | $5.4M | ||
| Q1 24 | — | $4.4M |
自由现金流PLXSWKH
| Q4 25 | $1.6M | $26.8M | ||
| Q3 25 | $-4.2M | $557.0K | ||
| Q2 25 | $-5.7M | $7.7M | ||
| Q1 25 | $-5.4M | $8.2M | ||
| Q4 24 | $3.6M | $22.9M | ||
| Q3 24 | $4.0M | $6.3M | ||
| Q2 24 | $-3.8M | $5.4M | ||
| Q1 24 | — | — |
自由现金流率PLXSWKH
| Q4 25 | 17.8% | 308.1% | ||
| Q3 25 | -23.7% | 5.1% | ||
| Q2 25 | -36.2% | 77.0% | ||
| Q1 25 | -53.0% | 69.1% | ||
| Q4 24 | 19.6% | 185.3% | ||
| Q3 24 | 22.4% | 60.4% | ||
| Q2 24 | -28.1% | 49.7% | ||
| Q1 24 | — | — |
资本支出强度PLXSWKH
| Q4 25 | 4.4% | 5.9% | ||
| Q3 25 | 2.8% | 3.2% | ||
| Q2 25 | 2.8% | 0.6% | ||
| Q1 25 | 3.0% | 0.8% | ||
| Q4 24 | 2.3% | 1.1% | ||
| Q3 24 | 0.5% | 0.3% | ||
| Q2 24 | 1.3% | 0.2% | ||
| Q1 24 | — | 0.0% |
现金转化率PLXSWKH
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | 0.10× | ||
| Q2 25 | -31.91× | 2.21× | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | 0.61× | 3.93× | ||
| Q3 24 | 1.27× | 1.82× | ||
| Q2 24 | — | 1.47× | ||
| Q1 24 | — | 9.47× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SWKH
| Finance Receivables Segment | $8.4M | 96% |
| Other | $329.0K | 4% |
